Tran Trang graduated with a PhD in Life Science in 2011 at the University of Burgundy and has broad experience from in vitro target discovery up to preclinical candidate selection in metabolism and immuno-inflammation area. During her postdoc at Sanofi, she worked on anti-PCSK9 antibody (Praluent), an efficient cholesterol-lowering agent in dyslipidemia and atherosclerosis. Working as Project manager within Danone research, she was in charge probiotic screening and preclinical evaluation in metabolic diseases.
During the last 5 years at Tridek-One, she has successfully developed and implemented cell-based bioassays exploring the mechanism of action and screening of therapeutic antibodies targeting CD31.